MarketCapExport financials
Senseonics Holdings (SENS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Senseonics Holdings Balance Sheet 2025-2011 | SENS
Brief overview of Senseonics Holdings's financial position
The comparison uses five available annual reports from the 2021–2025 interval.
Assets declined from $198.9 million to $126.3 million, or -36.5%. The contraction calls for context such as disposals, restructuring or weaker operations.
Liabilities grew more slowly than assets: -83% versus -36.5%. Expansion relied more on equity, improving funding quality.
Equity finances 48.3% of the balance sheet, compared with -93.3% at the start. The cushion remains adequate.
Net debt moved below zero to -$4.2 million, reflecting surplus cash over debt.
Cash represents 31.9% of assets versus 16.8% initially, showing how the immediate liquidity reserve changed.
The accumulated result is -$1 billion and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Senseonics Holdings's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Senseonics Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-4.15 M | -39.5 M | -34.1 M | 21.3 M | 27.2 M | 42.4 M | 20.3 M | -85.9 M | 8.26 M | 6.02 M | -996 | -10 K | - | - | - |
Long Term Debt |
35.6 M | 34.7 M | 41.2 M | 56.4 M | 59.8 M | 57.2 M | 12.5 M | 40.9 M | 14.4 M | 15.2 M | - | - | - | - | - |
Long Term Debt Current |
496 K | 429 K | 368 K | 725 K | 904 K | 794 K | 696 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 163 M | 14.7 M | 59.8 M | 15.5 M | 15.5 M | - | - | - | - | - |
Total Current Liabilities |
24.3 M | 38.8 M | 17.3 M | 31.5 M | 18.4 M | 16.6 M | 127 M | 28.9 M | 23.1 M | 11.6 M | 7.34 M | - | - | - | - |
Total Liabilities |
65.2 M | 79.3 M | 64.8 M | 143 M | 384 M | 180 M | 141 M | 88.7 M | 38.7 M | 27.1 M | 46.5 K | 2.92 K | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 628 K | - | - | - | - | - | - | - |
Retained Earnings |
-1.02 B | -948 M | -869 M | -809 M | -951 M | -649 M | -473 M | -358 M | -264 M | -205 M | -70.5 K | -2.92 K | - | - | - |
Total Assets |
126 M | 100 M | 138 M | 178 M | 199 M | 35.9 M | 133 M | 160 M | 45.9 M | 22.3 M | 996 | 10 K | - | - | - |
Cash and Cash Equivalents |
40.2 M | 74.6 M | 75.7 M | 35.8 M | 33.5 M | 18 M | 95.9 M | 137 M | 16.2 M | 13 M | 3.94 M | 18.9 M | 8.25 M | - | - |
Book Value |
61 M | 21.1 M | 73.5 M | 35.1 M | -186 M | -144 M | -8.65 M | 71.3 M | 7.27 M | -4.88 M | -45.5 K | 7.08 K | - | - | - |
Total Shareholders Equity |
61 M | -16.6 M | 35.8 M | -2.58 M | -186 M | -144 M | -8.65 M | 71.3 M | 7.27 M | -4.88 M | -9.7 M | 7.91 M | 6.16 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Senseonics Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
55.8 M | 35.9 M | 35.3 M | 35.2 M | 35 M | 34.7 M | 34.4 M | 34.2 M | 34 M | 41.2 M | 40.5 M | 39.1 M | 37.5 M | 56.4 M | 53.4 M | 50.6 M | 48 M | 59.8 M | 57.2 M | 54.7 M | 52.9 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 11.8 M | 11.8 M | 11.8 M | 1.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
86.5 M | 68.5 M | 61.8 M | 55.6 M | 52 M | 79.3 M | 75.9 M | 73.3 M | 69.9 M | 64.8 M | 64.3 M | 63.2 M | 56.4 M | 143 M | 198 M | 159 M | 278 M | 384 M | 486 M | 548 M | 382 M | 177 M | 177 M | 177 M | 177 M | 141 M | 141 M | 141 M | 141 M | 88.7 M | 88.7 M | 88.7 M | 88.7 M | 38.7 M | 38.7 M | 38.7 M | 38.7 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 15.1 M | 15.2 M | 15.2 M | 15.2 M | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 628 K | 628 K | 628 K | 628 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.09 B | -1.05 B | -996 M | -977 M | -962 M | -948 M | -932 M | -908 M | -888 M | -869 M | -852 M | -828 M | -808 M | -809 M | -820 M | -760 M | -864 M | -951 M | -1.04 B | -1.08 B | -898 M | -649 M | -649 M | -649 M | -649 M | -473 M | -473 M | -473 M | -473 M | -358 M | -358 M | -358 M | -358 M | -264 M | -264 M | -264 M | -264 M | -205 M | -205 M | -205 M | -205 M | -161 M | -161 M | -161 M | -161 M | -131 M | -2.92 K | -27.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
177 M | 103 M | 140 M | 150 M | 87.2 M | 100 M | 96.3 M | 112 M | 127 M | 138 M | 154 M | 153 M | 159 M | 178 M | 183 M | 175 M | 188 M | 199 M | 220 M | 235 M | 196 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 133 M | 133 M | 133 M | 133 M | 160 M | 160 M | 160 M | 160 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 22.3 M | 22.3 M | 22.3 M | 22.3 M | 5.42 M | 5.49 M | 5.49 M | 5.49 M | 20 M | 4.42 K | 17.2 K | 10 K | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
44.8 M | 29.6 M | 34.5 M | 31.5 M | 39.3 M | 74.6 M | 27.4 M | 35.2 M | 90.9 M | 75.7 M | 55.8 M | 28.6 M | 45.1 M | 35.8 M | 35.5 M | 45.4 M | 39 M | 33.5 M | 46.2 M | 69.8 M | 179 M | 18.2 M | 18 M | 18 M | 18 M | 95.9 M | 95.9 M | 95.9 M | 95.9 M | 137 M | 137 M | 137 M | 137 M | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 13 M | 13 M | 13 M | 13 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 18.9 M | 4.42 K | 10 K | 4.42 K | 8.25 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
90.3 M | 34.3 M | 78.2 M | 94.7 M | 35.2 M | 21.1 M | 20.5 M | 38.2 M | 56.6 M | 73.5 M | 89.7 M | 90.2 M | 102 M | 35.1 M | -15.1 M | 15.9 M | -89.5 M | -186 M | -267 M | -313 M | -186 M | -141 M | -141 M | -141 M | -141 M | -8.65 M | -8.65 M | -8.65 M | -8.65 M | 71.3 M | 71.3 M | 71.3 M | 71.3 M | 7.27 M | 7.27 M | 7.27 M | 7.27 M | -4.88 M | -4.88 M | -4.88 M | -4.88 M | -9.7 M | -9.7 M | -9.7 M | -9.7 M | 7.91 M | 4.42 K | 17.2 K | 10 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
90.3 M | 34.3 M | 78.2 M | 94.7 M | 35.2 M | -16.6 M | -17.2 M | 578 K | 19 M | 35.8 M | 52.1 M | 52.5 M | 64.5 M | -2.58 M | -15.1 M | 15.9 M | -89.5 M | -186 M | -267 M | -313 M | -186 M | -144 M | -144 M | -144 M | -144 M | -8.65 M | -8.65 M | -8.65 M | -8.65 M | 71.3 M | 71.3 M | 71.3 M | 71.3 M | 7.27 M | 7.27 M | 7.27 M | 7.27 M | -4.88 M | -4.88 M | -4.88 M | -4.88 M | -9.7 M | -9.7 M | -9.7 M | -9.7 M | 7.91 M | -14.6 K | -2.2 K | 7.08 K | 6.16 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Senseonics Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |